These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1981012)

  • 1. Somatostatin analogues in the treatment of breast and prostate cancer.
    Manni A; Boucher AE; Demers LM; Harvey HA; Lipton A; Simmonds MA; Bartholomew M
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1083-7. PubMed ID: 1981012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial inhibition of the growth of transplanted dunning rat prostate tumors with the long-acting somatostatin analogue sandostatin (SMS 201-995).
    Siegel RA; Tolcsvai L; Rudin M
    Cancer Res; 1988 Aug; 48(16):4651-5. PubMed ID: 2899458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma.
    Vainas G; Pasaitou V; Galaktidou G; Maris K; Christodoulou K; Constantinidis C; Kortsaris AH
    J Exp Clin Cancer Res; 1997 Mar; 16(1):119-26. PubMed ID: 9148872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin and growth hormone regulation in cancer.
    Manni A
    Biotherapy; 1992; 4(1):31-6. PubMed ID: 1347453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology.
    Di Leo A; Ferrari L; Bajetta E; Bartoli C; Vicario G; Moglia D; Miceli R; Callegari M; Bono A
    Breast Cancer Res Treat; 1995 Jun; 34(3):237-44. PubMed ID: 7579488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial on sms-D70 somatostatin analogue in advanced prostate and renal cell cancer.
    Joensuu TK; Nilsson S; Holmberg AR; Márquez M; Tenhunen M; Saarto T; Joensuu H
    Ann N Y Acad Sci; 2004 Dec; 1028():361-74. PubMed ID: 15650261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatostatin and analogues in the treatment of cancer. A review.
    Evers BM; Parekh D; Townsend CM; Thompson JC
    Ann Surg; 1991 Mar; 213(3):190-8. PubMed ID: 1671812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment approaches for prostate cancer based on peptide analogues.
    Stangelberger A; Schally AV; Djavan B
    Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.
    Manni A; Boucher AE; Demers LM; Harvey HA; Lipton A; Simmonds MA; Bartholomew M
    Breast Cancer Res Treat; 1989 Dec; 14(3):289-98. PubMed ID: 2575406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin-A, prostate-specific antigen, and insulin-like growth factor-1 in advanced prostate cancer patients.
    Berruti A; Dogliotti L; Mosca A; Tarabuzzi R; Torta M; Mari M; Gorzegno G; Fontana D; Angeli A
    Prostate; 2001 May; 47(3):205-11. PubMed ID: 11351350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
    Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Somatostatin analogs in oncology].
    Thomas F; Parmar H; Prevost G; Kuhn JM; Bejot JL; Moreau JP; Bogden A
    Bull Cancer; 1991; 78(8):693-707. PubMed ID: 1681967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dephosphorylation of cancer protein by tyrosine phosphatases in response to analogs of luteinizing hormone-releasing hormone and somatostatin.
    Lee LT; Schally AV; Liebow C; Lee PP; Lee PH; Lee MT
    Anticancer Res; 2008; 28(5A):2599-605. PubMed ID: 19035284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Somatostatin and somatostatin receptors in the prostate].
    Sinisi AA; Bellastella A; Pasquali D
    Minerva Endocrinol; 2001 Sep; 26(3):159-63. PubMed ID: 11753239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin].
    Schally AV
    An R Acad Nac Med (Madr); 2004; 121(3):493-500. PubMed ID: 15751842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for the use of somatostatin analogs as antitumor agents.
    Susini C; Buscail L
    Ann Oncol; 2006 Dec; 17(12):1733-42. PubMed ID: 16801334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of refractory prostate cancer with somatostatin analogues and glucocorticoids.
    Trafalis DT; Athanassiou AE
    J BUON; 2008; 13(2):295-6. PubMed ID: 18555482
    [No Abstract]   [Full Text] [Related]  

  • 20. The potential role of somatostatin analogues in breast cancer treatment.
    Pollak M
    Yale J Biol Med; 1997; 70(5-6):535-9. PubMed ID: 9825480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.